JOP20220125A1 - مركبات حلقية غير متجانسة على هيئة مثبطات دلتا-5 ديساتوراز وطرق لاستخدامها - Google Patents

مركبات حلقية غير متجانسة على هيئة مثبطات دلتا-5 ديساتوراز وطرق لاستخدامها

Info

Publication number
JOP20220125A1
JOP20220125A1 JOP/2022/0125A JOP20220125A JOP20220125A1 JO P20220125 A1 JOP20220125 A1 JO P20220125A1 JO P20220125 A JOP20220125 A JO P20220125A JO P20220125 A1 JOP20220125 A1 JO P20220125A1
Authority
JO
Jordan
Prior art keywords
compounds
delta
methods
heterocyclic compounds
desaturase inhibitors
Prior art date
Application number
JOP/2022/0125A
Other languages
English (en)
Inventor
Jennifer R Allen
Michela Beltrani
Matthew P Bourbeau
Teodora P Damyanova
Paolo Vincetti
Iain Lingard
Ana E Minatti
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of JOP20220125A1 publication Critical patent/JOP20220125A1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

: يتعلق الاختراع الحالي بمركبات مفيدة لتثبيط دلتا-5 ديساتوراز ("D5D"). يكون للمركبات صيغة عامة I: I حيث يتم تعريف المتغيرات بالصيغة I في هذه الوثيقة. يقدم هذا الكشف أيضاً تركيبات صيدلانية تشتمل على المركبات، استخدامات المركبات، وتركيبات لمعالجة، على سبيل المثال، اضطراب أيضي أو قلبي وعائي. علاوة على ذلك، يوفر الكشف مركبات وسيطة مفيدة في تخليق المركبات بالصيغة I.
JOP/2022/0125A 2019-11-25 2020-11-24 مركبات حلقية غير متجانسة على هيئة مثبطات دلتا-5 ديساتوراز وطرق لاستخدامها JOP20220125A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962939821P 2019-11-25 2019-11-25
PCT/US2020/062020 WO2021108408A1 (en) 2019-11-25 2020-11-24 Heterocyclic compounds as delta-5 desaturase inhibitors and methods of use

Publications (1)

Publication Number Publication Date
JOP20220125A1 true JOP20220125A1 (ar) 2023-01-30

Family

ID=73855555

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2022/0125A JOP20220125A1 (ar) 2019-11-25 2020-11-24 مركبات حلقية غير متجانسة على هيئة مثبطات دلتا-5 ديساتوراز وطرق لاستخدامها

Country Status (19)

Country Link
US (3) US11512097B2 (ar)
EP (1) EP4065223A1 (ar)
JP (2) JP7254246B2 (ar)
KR (2) KR102598203B1 (ar)
CN (1) CN114728167B (ar)
AR (1) AR120556A1 (ar)
AU (1) AU2020392087A1 (ar)
BR (1) BR112022010054A2 (ar)
CA (1) CA3162281A1 (ar)
CL (2) CL2022001357A1 (ar)
CO (1) CO2022008690A2 (ar)
CR (1) CR20220308A (ar)
IL (1) IL293191A (ar)
JO (1) JOP20220125A1 (ar)
MX (1) MX2022006281A (ar)
PE (1) PE20231097A1 (ar)
TW (1) TWI815061B (ar)
UY (1) UY38971A (ar)
WO (1) WO2021108408A1 (ar)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20220308A (es) 2019-11-25 2022-08-04 Amgen Inc Compuestos heterocíclicos como inhibidores de delta-5 desaturasa y métodos de uso
CN115557903A (zh) * 2022-09-27 2023-01-03 山东潍坊润丰化工股份有限公司 一种特草定的制备方法

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3130633A1 (de) 1981-08-01 1983-02-17 Basf Ag, 6700 Ludwigshafen 7-amino-azolo(1,5-a)pyrimidine und diese enthaltende fungizide
ES2058069T3 (es) 1986-04-07 1994-11-01 Kumiai Chemical Industry Co Derivados de 5h-1,3,4-tiadiazolo-(3,2-a)-pirimidin-5-ona y nuevo compuesto fungicida agricola-horticola que contiene dicho derivado.
CN1328277C (zh) 1996-12-05 2007-07-25 安姆根有限公司 取代的嘧啶酮和吡啶酮化合物和它们的应用
US6096753A (en) 1996-12-05 2000-08-01 Amgen Inc. Substituted pyrimidinone and pyridone compounds and methods of use
US6537998B1 (en) * 1999-10-15 2003-03-25 Neurocrine Biosciences, Inc. Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
DE60022769T2 (de) 1999-10-15 2006-07-06 Neurocrine Biosciences, Inc., San Diego Gonadotropin freisetzenden hormon rezeptor antagonisten und ihre verwandten verwendungen
AU2003238157A1 (en) 2002-06-18 2003-12-31 Sankyo Company, Limited Fused-ring pyrimidin-4(3h)-one derivatives, processes for the preparation and uses thereof
JP2004107228A (ja) 2002-09-17 2004-04-08 Nippon Nohyaku Co Ltd 双環性ピリミジノン誘導体及びこれを有効成分とする除草剤
PE20051089A1 (es) 2004-01-22 2006-01-25 Novartis Ag Derivados de pirazolo [1,5-a] pirimidin-7-il-amina como inhibidores de quinasa de proteina
US20050222171A1 (en) 2004-01-22 2005-10-06 Guido Bold Organic compounds
EP1917250B1 (en) 2005-06-27 2010-07-21 Amgen, Inc Anti-inflammatory aryl nitrile compounds
WO2007027012A1 (en) 2005-07-18 2007-03-08 Samsung Electronics Co., Ltd. Video coding method and apparatus for reducing mismatch between encoder and decoder
BRPI0613912A2 (pt) 2005-07-27 2016-11-22 Basf Ag compostos, processo para preparar compostos, agente fungicida, semente, e, método para combater fungos nocivos fitopatogênicos
JP2009502863A (ja) 2005-07-27 2009-01-29 ビーエーエスエフ ソシエタス・ヨーロピア ６−フェニル−ピラゾロピリミジン−７−イルアミン殺菌剤
JP2009502864A (ja) 2005-07-27 2009-01-29 ビーエーエスエフ ソシエタス・ヨーロピア 殺菌性の５−メチル−６−フェニルトリアゾロピリミジニルアミン
CN101360499B (zh) 2005-10-06 2015-10-07 默沙东公司 吡唑并[1,5-a]嘧啶衍生物在制备抑制蛋白激酶的药物中的用途
RU2009115784A (ru) 2006-09-28 2010-11-10 Новартис АГ (CH) Производные пиразоло[1,5-а]пиримидина и их применение в медицине
WO2008057601A2 (en) 2006-11-08 2008-05-15 The Rockefeller University Organic compounds
US20080200458A1 (en) 2007-01-18 2008-08-21 Joseph Barbosa Methods and compositions for the treatment of body composition disorders
US20080194557A1 (en) 2007-01-18 2008-08-14 Joseph Barbosa Methods and compositions for the treatment of pain, inflammation and cancer
JP5457198B2 (ja) 2007-01-19 2014-04-02 ビーエーエスエフ ソシエタス・ヨーロピア １−メチルピラゾール−４−イルカルボン酸アニリド類とアゾロピリミジニルアミン類の殺菌剤混合物
WO2008092836A2 (en) 2007-01-30 2008-08-07 Basf Se Method for improving plant health
US8461077B2 (en) 2007-03-23 2013-06-11 Basf Se Combinations of active substances
CA2709784A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
WO2009124259A1 (en) 2008-04-04 2009-10-08 Cv Therapeutics, Inc. Pyrrolotriazinone derivatives for use as stearoyl coa desaturase inhibitors
US8119647B2 (en) * 2008-04-23 2012-02-21 Glenmark Pharmaceuticals S.A. Fused pyrimidineone compounds as TRPV3 modulators
UY32395A (es) 2009-01-27 2010-08-31 Takeda Pharmaceutical Compuesto con anillo fusionado y su uso
MY162507A (en) 2009-06-29 2017-06-15 Incyte Holdings Corp Pyrimidinones as pi3k inhibitors
WO2011114148A1 (en) * 2010-03-17 2011-09-22 Astrazeneca Ab 4h- [1, 2, 4] triazolo [5, 1 -b] pyrimidin-7 -one derivatives as ccr2b receptor antagonists
JPWO2012011592A1 (ja) 2010-07-23 2013-09-09 武田薬品工業株式会社 複素環化合物およびその用途
US9108984B2 (en) 2011-03-14 2015-08-18 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors
WO2013177538A2 (en) 2012-05-24 2013-11-28 Colorado State University Research Foundation Inhibition of delta-6 desaturase for the treatment of cardiometabolic disease
US20140275092A1 (en) 2013-03-13 2014-09-18 Constellation Pharmaceuticals, Inc. Pyrazolo compounds and uses thereof
KR20160049003A (ko) 2013-09-05 2016-05-04 제넨테크, 인크. 항증식성 화합물
WO2015064714A1 (ja) 2013-10-31 2015-05-07 国立大学法人東京大学 オートタキシン阻害活性を有する１－置換イミダゾピリミジノン誘導体
WO2015135094A1 (en) 2014-03-13 2015-09-17 Genentech, Inc. Therapeutic compounds and uses thereof
US10065972B2 (en) 2014-04-23 2018-09-04 Mitsubishi Tanabe Pharma Corporation Bicyclic or tricyclic heterocyclic compound
US9988401B2 (en) 2015-05-11 2018-06-05 Incyte Corporation Crystalline forms of a PI3K inhibitor
JP6791717B2 (ja) 2015-10-22 2020-11-25 田辺三菱製薬株式会社 医薬組成物
EP3394032A4 (en) 2015-12-21 2019-09-18 The University of Chicago COMPOUNDS AND METHODS OF TREATMENT, DETECTION AND IDENTIFICATION OF COMPOUNDS FOR THE TREATMENT OF PARASITIC ILLNESSES BY APICOMPLEXA
KR102411150B1 (ko) 2016-08-31 2022-06-21 아지오스 파마슈티컬스 아이엔씨. 세포 대사 과정의 억제제
WO2018039972A1 (en) * 2016-08-31 2018-03-08 Agios Pharmaceuticals, Inc. Inhibitors of cellular metabolic processes
CN106749271B (zh) 2016-12-07 2019-04-05 青岛科技大学 一类[1,2,4]-三氮唑并[1,5-a]嘧啶酮类杂环化合物、其制备方法及其用途
SG11201910197SA (en) 2017-05-15 2019-11-28 Dana Farber Cancer Inst Inc Compounds for treating dengue virus infection and other viral infections
WO2018229683A1 (en) 2017-06-15 2018-12-20 Novartis Ag 5,6-fused-bicyclic compounds and compositions for the treatment of parasitic diseases
MX2020002869A (es) 2017-09-15 2020-07-24 Aduro Biotech Inc Compuestos de pirazolopirimidinona y usos de los mismos.
CR20220308A (es) 2019-11-25 2022-08-04 Amgen Inc Compuestos heterocíclicos como inhibidores de delta-5 desaturasa y métodos de uso

Also Published As

Publication number Publication date
CA3162281A1 (en) 2021-06-03
TWI815061B (zh) 2023-09-11
AU2020392087A1 (en) 2022-06-09
CL2022001357A1 (es) 2023-03-10
US20230159560A1 (en) 2023-05-25
CN114728167B (zh) 2024-03-19
CO2022008690A2 (es) 2022-06-30
BR112022010054A2 (pt) 2022-08-16
US20210188874A1 (en) 2021-06-24
CL2023002486A1 (es) 2024-01-12
IL293191A (en) 2022-07-01
TW202132317A (zh) 2021-09-01
KR102598203B1 (ko) 2023-11-03
KR20220106159A (ko) 2022-07-28
CN114728167A (zh) 2022-07-08
EP4065223A1 (en) 2022-10-05
UY38971A (es) 2021-06-30
JP2023078418A (ja) 2023-06-06
KR20230154292A (ko) 2023-11-07
US11512097B2 (en) 2022-11-29
AR120556A1 (es) 2022-02-23
CR20220308A (es) 2022-08-04
WO2021108408A1 (en) 2021-06-03
PE20231097A1 (es) 2023-07-18
US20210221824A1 (en) 2021-07-22
JP2022549739A (ja) 2022-11-28
JP7254246B2 (ja) 2023-04-07
MX2022006281A (es) 2022-06-08

Similar Documents

Publication Publication Date Title
CR20200376A (es) Inhibidores de cd73
MX2021000795A (es) Compuestos heterociclicos para inhibir la actividad de shp2.
MX2021006026A (es) Pirimidina y derivado heterociclico de nitrogeno de cinco miembros, metodo de preparacion y usos medicos de los mismos.
MX2022010011A (es) Inhibidores de prmt5 novedosos.
NZ592425A (en) Isoindoline compounds for use in the treatment of cancer
MX2023007192A (es) Inhibidores de prmt5.
GEP20115304B (en) PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kα
GEP20166443B (en) Heterocyclic compound and use thereof
MY152271A (en) Novel compounds that are erk inhibitors
EA201001669A1 (ru) Замещенные пиримидин-5-карбоксамиды 281
TN2010000293A1 (en) Thiazole derivatives used as pi 3 kinase inhibitors
MX2009012708A (es) Derivados de piridazinona.
TW200745066A (en) Novel PTP1B inhibitors
MX2010002938A (es) Derivados de (3-hidroxi-4-amino-butan-2-il)-3-(2-tiazol-2-il-pirro lidin-1-carbonil)benzamida y compuestos relacionados como inhibidores de beta-secretasa para tratar enfermedad de alzheimer.
MX2020010181A (es) Compuestos de piperidina como inhibidores covalentes de menina.
MX2019011412A (es) Piperidinas como inhibidores de menina covalentes.
MX2019013561A (es) Compuestos de pirrolopiridina-anilina para el tratamiento de trastornos dermicos.
MX2022000550A (es) Imidazopirimidinas como inhibidores de eed y uso de estas.
MX2019010096A (es) Derivados de 1, 4, 6-trisustituidos-2-alquil-1h-benzo[d]imidazol como inhibidores de dihidroorotato oxigenasa.
MX2011011764A (es) Compuestos de carboxamida y su uso como inhibidores de calpaina.
MX2022006281A (es) Compuestos heterociclicos como inhibidores de delta-5 desaturasa y metodos de uso.
MX2021003843A (es) Inhibidores de la interaccion yap/taz-tead y su uso en el tratamiento del cancer.
MX2020001531A (es) Nuevos compuestos hetorociclicos como inhibidores de cdk8/19.
EA201100872A1 (ru) Производные хиназолинамида
MX2010007543A (es) Inhibidores de iap.